COVID-19 Saliva Screening Test Potential Market Report 2026

The COVID-19 saliva screening test potential market size has grown strongly in recent years. It will grow from $4.28 billion in 2025 to $4.69 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to discomfort of swab-based testing, need for frequent screening, infection control concerns, demand for scalable testing solutions, public health emergency response.

The COVID-19 saliva screening test potential market size is expected to see strong growth in the next few years. It will grow to $6.46 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to future pandemic preparedness strategies, growth of decentralized diagnostics, expansion of workplace testing, cost-effective mass screening demand, innovation in saliva-based technologies. Major trends in the forecast period include shift toward non-invasive testing methods, expansion of large-scale community screening, growing acceptance of self-collection testing, deployment in high-traffic public locations, integration with workplace safety programs.

The increase in healthcare expenditure is expected to drive the growth of the COVID-19 saliva screening test potential market in the coming years. Healthcare expenditure refers to the total spending on healthcare-related goods and services, including prescription medications, hospital admissions, physician consultations, medical equipment, and public health initiatives. Healthcare spending continues to rise due to factors such as the adoption of minimally invasive procedures, the use of advanced diagnostic technologies, increased investment in research and development for new drugs, higher utilization of healthcare services, and the growing use of specialty medications. Higher healthcare expenditure provides the necessary financial resources and infrastructure to fully utilize the potential of COVID-19 saliva screening tests, supporting more effective pandemic management and improved public health outcomes. For example, in December 2024, according to the U.S. Centers for Medicare and Medicaid Services (CMS), a US-based federal health agency, national healthcare spending increased by 7.5 percent to reach US $4.9 trillion compared to the previous year. Therefore, rising healthcare expenditure is contributing to the growth of the COVID-19 saliva screening test potential market.

Major companies operating in the COVID-19 saliva screening test potential market are concentrating on the development of innovative technologies, such as data-sharing platforms, to improve real-time communication and collaboration among healthcare providers, laboratories, and public health authorities. These efforts aim to enhance the efficiency and accuracy of testing, monitoring, and response activities during the pandemic. Data-sharing platforms are digital systems that allow the secure exchange of information among stakeholders including healthcare providers, researchers, and organizations, supporting better collaboration, improved access to information, and more informed decision-making. For instance, in May 2024, Mount Sinai Health System, a US-based healthcare network, launched the Center for Healthcare Readiness. The center focuses on strengthening public health emergency response strategies to ensure healthcare systems can effectively manage large-scale crises such as pandemics or natural disasters. It also seeks to expand the capacity of the Mount Sinai Health System while working with local, regional, and federal partners to develop comprehensive preparedness plans.

In July 2024, Hologic, Inc., a US-based health technology company, acquired Endomagnetics Ltd. for an undisclosed amount. Through this acquisition, Hologic aims to strengthen its portfolio of innovative healthcare solutions and broaden its presence in the women’s health market. Endomagnetics Ltd. is a UK-based medical technology company that develops medical devices used to detect cancerous lymph nodes during surgical procedures.

Major companies operating in the COVID-19 saliva screening test potential market are Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson and Company, Danaher Corporation, University of North Carolina at Chapel Hill, Hologic Inc., Beaumont Health, PerkinElmer Inc., Quidel Corporation, University of Illinois at Urbana-Champaign, Cepheid, Seegene Inc., ARUP Laboratories, Vatic Health Limited, Ambry Genetics Corporation, LumiraDx Ltd., Yale School of Public Health, Gravity Diagnostics, Psomagen Inc., Fluidigm Corporation, Phosphorus Diagnostics LLC, DxTerity Diagnostics Inc., University of Notre Dame, MOgene.

North America was the largest region in the COVID-19 saliva screening test potential market in 2025. The regions covered in the COVID-19 saliva screening test potential market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the COVID-19 saliva screening test potential market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the COVID-19 saliva screening test potential market by increasing costs of imported reagents, diagnostic platforms, sample collection materials, and laboratory equipment. Public testing programs in North America and Europe are most affected due to reliance on imported technologies, while Asia-Pacific faces higher deployment costs. These tariffs are increasing screening expenses. However, they are also supporting local test development, domestic manufacturing, and broader diagnostic accessibility.

The COVID-19 saliva screening test potential market research report is one of a series of new reports that provides COVID-19 saliva screening test potential market statistics, including COVID-19 saliva screening test potential industry global market size, regional shares, competitors with a COVID-19 saliva screening test potential market share, detailed COVID-19 saliva screening test potential market segments, market trends and opportunities, and any further data you may need to thrive in the COVID-19 saliva screening test potential industry. This COVID-19 saliva screening test potential market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The COVID-19 saliva screening test potential refers to the possible benefits and capabilities of saliva-based tests for detecting SARS-CoV-2, the virus responsible for COVID-19, when compared with conventional testing methods such as nasopharyngeal or oropharyngeal swab tests. This potential includes improved testing accessibility, higher patient acceptance, greater cost efficiency, and enhanced safety, while also supporting new testing strategies and approaches to more effectively manage the COVID-19 pandemic.

The primary locations where COVID-19 saliva screening tests may be deployed include travel stations, sports arenas, entertainment venues, corporate campuses, universities and colleges, factories, and other locations. Travel stations are specific areas within transportation hubs where individuals can undergo COVID-19 saliva screening prior to travel. The technologies used in these tests include fluorescence-labeled antigen assays, RT-PCR, and CRISPR-Cas9, and the testing modes include centralized testing and decentralized testing.

The COVID-19 saliva screening test potential market consist revenues earned by entities by providing services such as sample collection services, laboratory testing services, diagnostic reporting services, and screening and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The COVID-19 saliva screening test potential market also consists of sales of saliva collection kits, rapid saliva testing kits, laboratory testing supplies, and automated sample processing systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.